•
CL
CLDX
Celldex Therapeutics, Inc
yahooIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
--
Price Chart
Market Cap
1.74B
Volume
7.88K
52W High
$30.50
52W Low
$14.40
Open
$0.00
Prev Close
$26.17
Day Range
0.00 - 0.00
About Celldex Therapeutics, Inc
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Latest News
Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma
GlobeNewswire Inc.•Aug 27
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
GlobeNewswire Inc.•Jun 14
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
GlobeNewswire Inc.•Mar 3
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
GlobeNewswire Inc.•Mar 1
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight
GlobeNewswire Inc.•Feb 20
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
GlobeNewswire Inc.•Dec 19
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight
GlobeNewswire Inc.•Nov 4
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
GlobeNewswire Inc.•Oct 26